Abstract 1589P
Background
In addition to the structural/medical barriers that trial centres face in including patients, the disparities that patients face prevents some groups from receiving the expected benefit from the studies and the results from representing the entire population. This study assessed the barriers to recruiting individuals in phase one trials who were referred to clinical research facility located in central London.
Methods
Records of patients who were referred to Guy's Cancer Early Phase Trials Unit between January and December 2023 were retrospectively reviewed. Baseline patient characteristics and barriers to trial enrolment were recorded and descriptive statistics were presented. The distrubition of new referrals by age, cancer types, ethnicity, and socioeconomic status defined by Index of Multiple Deprivation (IMD,1 - most deprived; 10 - least deprived) was also assessed by comparing with our group's historic data published in 2013 in Journal of Clinical Oncology.
Results
We reviewed 206 new patients in 2023. Median age of the group was 63, and 52.4% of patient were male. GI, thoracic, gyneacological and urological malignancies were the most common tumour groups (37%, 19%, 18%, and 14% respectively). Of whole group, 33.9% of patients were referred after two lines of previous treatment. 37 patients (17.9%) were recruited to a trial annually. Most common barrier to be recruited to a trial is that the center has no potential trial to offer (N=59, 35.9%), followed by failure to meet radiological criteria (11.2%), and poor performance status (10.0%) 22 patients (10.6%) were from most deprivated (IMD 1-2) background. Our historic data from 2013 showed 21.9% of patients had been referred from most deprivated background. There was a white-ethnicitiy domination in current and historic data (71.5% and 74.2%, retrospectively).
Conclusions
An increasing number of new patients are being referred to our centre. Among the prominent recruitment barriers are the lack of appropriate studies and non-compliance with medical criteria. The decrease in the rate of patients from low socioeconomic backgrounds is striking compared to the historical data of our center. Further efforts should be made to identify the potential causes of this situation and to improve it.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1607P - Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304)
Presenter: Lisa Horvath
Session: Poster session 10
1608P - Prostate cancer working group 4 (PCWG4) preliminary criteria using serial PSMA PET/CT for response evaluation: Analysis from the PRINCE trial
Presenter: Michael Hofman
Session: Poster session 10
1609P - PSMA-PET and PROMISE re-define stage and risk in patients with prostate cancer
Presenter: Wolfgang Fendler
Session: Poster session 10
1610P - Circulating tumour cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig
Presenter: Andrew Armstrong
Session: Poster session 10
1611P - Haematologic impact of [177Lu]Lu-PSMA-617 versus ARPI change in patients with metastatic castration-resistant prostate cancer in PSMAfore
Presenter: Kim Nguyen Chi
Session: Poster session 10
1612P - Impact of FANCA, ATM, CDK12 alterations on survival in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: David Lorente
Session: Poster session 10
1613P - Clinically advanced prostate cancer (CAPC) featuring BRCA2 loss: A comprehensive genomic profiling (CGP) study
Presenter: Chiara Mercinelli
Session: Poster session 10
1614P - PSA responses and PSMA scan changes after immunotherapy for biochemically recurrent prostate cancer (BCR) without androgen deprivation therapy (ADT)
Presenter: Ravi Madan
Session: Poster session 10
1615P - A new prognostic model of overall survival (OS) in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC)
Presenter: Susan Halabi
Session: Poster session 10